Viewing Study NCT05228951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2026-01-13 @ 7:45 AM
Study NCT ID: NCT05228951
Status: RECRUITING
Last Update Posted: 2022-09-13
First Post: 2022-01-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Sponsor: Shengjing Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None breast cancer View
None pyrotinib maleate View
None letrozole View
None SHR6390 View
None trastuzumab View
None dalpiciclib View